Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Der p Alutard SQ
- Development stage
- Phase 4
- Lead developer
- ALK Abelló
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Der p Alutard SQ is a standardized allergen extract used for allergen-specific immunotherapy (allergy vaccination) targeting house dust mite (Dermatophagoides pteronyssinus) allergy. It is administered as a subcutaneous injection and works by gradually exposing the immune system to increasing doses of the allergen to induce immunological tolerance. This process modulates the immune response and reduces allergic symptoms over time. The product is developed primarily for the treatment of allergic rhinitis and asthma caused by house dust mites. The active ingredient consists of purified extracts from house dust mites adsorbed onto aluminium hydroxide as an adjuvant to enhance immune modulation[1][5][6][7].
- Brand names
- Alutard SQDer p Alutard SQAlutard Der p
- Other names
- House dust mite allergy vaccine injection - Alk-AbelloHouse dust mite SCIT - ALk-Abello
02
Targets
HLA-DR (Human leukocyte antigen DR)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on Der p Alutard SQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Der p Alutard SQ.